Abstract

Painful vaso-occlusive crisis (VOC) remains the most common reason for presenting to the Emergency Department and hospitalization in patients with sickle cell disease (SCD). Although two new agents have been approved by the Food and Drug Administration for treating SCD, they both target to reduce the frequency of VOC. Results from studies investigating various approaches to treat and shorten VOC have so far been generally disappointing. In this paper, we will summarize the complex pathophysiology and downstream events of VOC and discuss the likely reasons for the disappointing results using monotherapy. We will put forward the rationale for exploring some of the currently available agents to either protect erythrocytes un-involved in the hemoglobin polymerization process from sickling induced by the secondary events, or a multipronged combination approach that targets the complex downstream pathways of VOC.

MeSH

Cells, Anemia, Sickle Cell, Biomedical Research, Vaso-Occlusive Crises

Cited by

• Can we use biomarkers to identify those at risk of acute pain from sickle cell disease? Expert Rev Hematol, 2024
• GBT1118, a Voxelotor Analog, Ameliorates Hepatopathy in Sickle Cell Disease. Medicina (Kaunas), 2024
• The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol, 2022
• Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. J Clin Med, 2022
• The impact of comorbidities on the prognosis of patients with septic arthritis. Front Med (Lausanne), 2025
• New frontiers in sickle cell disease: The role of antiviral therapies and emerging drugs in managing viral infections. World J Virol, 2025
• Are children with sickle cell disease at particular risk from the harmful effects of air pollution? Evidence from a large, urban/peri-urban cohort. Pediatr Blood Cancer, 2023
• Polymorphic Distribution of Human Homeostatic Iron Regulator Gene H63D rs1799945 and Clinico-Hematological Parameters of Sickle Cell Anemia Patients: A Case-Control Study in Northern Ghana. Health Sci Rep, 2025
• Rheumatological picture of a patient having multifocal osteonecrosis associated with sickle cell anemia: a case study. Am J Blood Res, 2022
• Use of the microfluidic impedance red cell assay in sickle cell disease. Blood Adv, 2025
• Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis. Ann Hematol, 2025
• Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. Front Med (Lausanne), 2022
• Association between trauma triage and time-to-vaso-occlusive events in patients with sickle cell disease after traumatic injury: a retrospective study. Trauma Surg Acute Care Open, 2023
• Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease. J Proteome Res, 2025
• The involvement of mitochondria in erythrocyte pathology and diseases: from mechanisms to therapeutic strategies. Clin Exp Med, 2025
• Indications for hospitalisation and predictors of 30-day re-admission of patients with sickle cell disease in Uganda: a retrospective study. BMJ Open, 2025
• Increased retention of functional mitochondria in mature sickle red blood cells is associated with increased sickling tendency, hemolysis and oxidative stress. Haematologica, 2023
• Intestinal barrier functions in hematologic and oncologic diseases. J Transl Med, 2023
• Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity. Front Immunol, 2024